A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Completed · Phase 3

Conditions studied: Acute Moderate-to-severe Pain

In brief

This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.

Key facts

Study ID

NCT02662556

Run by

Talphera, Inc

People needed

140

Starts

2016-03-01

Expected to finish

2016-07-01

Last updated by the study team

2017-03-15

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients who are 40 years of age or older.
• Patients who have undergone a surgical procedure with general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.
• Patients classified as American Society of Anesthesiologists (ASA) class IIII (Appendix I).

You may not qualify if…

• Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
• Patients with a positive drug of abuse screen unless the positive test result is consistent with a prescribed medication.
• Patients with a history of opioid dependence within 2 years before the start of the study, defined as meeting the DSM-IV-TR™ Criteria for Substance Dependence specified in Appendix II.
• Patients who have used any illicit drugs of abuse within five years before the start of the study.
• Patients who have abused any prescription medication or alcohol within one year before the start of the study.
• Patients with an allergy or hypersensitivity to opioids.
• Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug.
• Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).

Where it is running

• HD Research — Houston, Texas, United States
• Research Concepts — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.